A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

(2021) Erica L Mayer et al.   LANCET ONCOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States

(2021) Qianyi Zhang et al.   HEALTH SERVICES RESEARCH

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

(2021) Sibylle Loibl et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis

(2021) Elizabeth M. Salvo et al.   BREAST

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

(2021) Andrew N.J. Tutt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

(2021) N. Harbeck et al.   ANNALS OF ONCOLOGY

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

(2021) Sharon H. Giordano et al.   JOURNAL OF CLINICAL ONCOLOGY

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

(2021) Kevin Kalinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Why Test for Proportional Hazards?

(2020) Mats J. Stensrud et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?

(2020) Antonio C. Wolff   JOURNAL OF CLINICAL ONCOLOGY

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

(2020) Stephen R. D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibitors for HR+HER2− early stage breast cancer — when to escalate treatment?

(2020) Giuseppe Curigliano   Nature Reviews Clinical Oncology

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients

(2020) Camille Moreau-Bachelard et al.   Cancers

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

(2020) Serena Di Cosimo et al.   BREAST

Liquid biopsy and minimal residual disease — latest advances and implications for cure

(2019) Klaus Pantel et al.   Nature Reviews Clinical Oncology

Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015

(2019) Robin Stuart-Harris et al.   BREAST

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer

(2018) Armando E. Giuliano et al.   ANNALS OF SURGICAL ONCOLOGY

Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence

(2018) Takeshi Murata et al.   Breast Journal

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

(2018) Nadia Howlader et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint

(2018) Melissa D. Curtis et al.   HEALTH SERVICES RESEARCH

Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients

(2018) Giovanni Corso et al.   ONCOLOGY

Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women

(2018) Tae In Yoon et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

(2018) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy

(2017) Fangbin Song et al.   OncoTargets and Therapy

Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations

(2017) Nikita Wright et al.   PLoS One

Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1–2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy

(2016) Shih-Fan Lai et al.   ANNALS OF SURGICAL ONCOLOGY

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years

(2016) Chiao-En Wu et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

The relationship between local recurrence and death in early-stage breast cancer

(2015) Victoria Sopik et al.   BREAST CANCER RESEARCH AND TREATMENT

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts

(2015) Christian Jackisch et al.   Breast Care

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy

(2015) S Baulies et al.   BRITISH JOURNAL OF CANCER

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

(2015) M. Dowsett et al.   CLINICAL CANCER RESEARCH

Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer

(2015) A. Kümmel et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

Hazard of Recurrence among Women after Primary Breast Cancer Treatment--A 10-Year Follow-up Using Data from SEER-Medicare

(2012) L. Cheng et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer

(2010) Carine A Bellera et al.   BMC Medical Research Methodology

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY